within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AJ01_Eculizumab;

model Eculizumab
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 3.587962962962963e-09,
    adminDuration = 600,
    adminMass = 900 / 1000000,
    adminCount = 1,
    Vd = 0.0055,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0031,
    k12 = 2.1990740740740743e-09,
    k21 = 2.1990740740740743e-09);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Eculizumab</td></tr><tr><td>ATC code:</td><td>L04AJ01</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>900</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>5.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.31</td><td>L/day</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Eculizumab is a monoclonal antibody that binds to complement protein C5, inhibiting terminal complement activation. It is used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), refractory generalized myasthenia gravis, and neuromyelitis optica spectrum disorder. The drug is approved and in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) after intravenous infusion.</p><h4>References</h4><ol><li><p>Brodsky, RA, et al., &amp; Hillmen, P (2008). Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. <i>Blood</i> 111(4) 1840–1847. DOI:<a href=\"https://doi.org/10.1182/blood-2007-06-094136\">10.1182/blood-2007-06-094136</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18055865/\">https://pubmed.ncbi.nlm.nih.gov/18055865</a></p></li><li><p>Saida, K, et al., &amp; Ito, S (2019). Pharmacokinetics and Pharmacodynamics Estimation of Eculizumab in a 2-Year-Old Girl With Atypical Hemolytic Uremic Syndrome: A Case Report With 4-Year Follow-Up. <i>Frontiers in pediatrics</i> 7 519–None. DOI:<a href=\"https://doi.org/10.3389/fped.2019.00519\">10.3389/fped.2019.00519</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31921730/\">https://pubmed.ncbi.nlm.nih.gov/31921730</a></p></li><li><p>Cosson, V, et al., &amp; Buatois, S (2025). Pharmacokinetic characterization and exposure-response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria. <i>British journal of clinical pharmacology</i> 91(5) 1479–1490. DOI:<a href=\"https://doi.org/10.1111/bcp.16394\">10.1111/bcp.16394</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39835421/\">https://pubmed.ncbi.nlm.nih.gov/39835421</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L04AJ01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Eculizumab;
